← Back to Screener
Niagen Bioscience, Inc. Common Stock (NAGE)
Price$4.73
Favorite Metrics
Price vs S&P 500 (26W)-40.19%
Price vs S&P 500 (4W)-1.65%
Market Capitalization$378.78M
P/E Ratio (Annual)21.79x
All Metrics
P/CF (Annual)28.05x
Book Value / Share (Quarterly)$0.96
P/TBV (Annual)7.16x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)21.56%
Cash Flow / Share (Quarterly)$0.17
Price vs S&P 500 (YTD)-28.11%
Gross Margin (TTM)64.28%
Net Profit Margin (TTM)13.43%
EPS (TTM)$0.20
10-Day Avg Trading Volume0.60M
EPS Excl Extra (TTM)$0.20
Revenue Growth (5Y)16.91%
EPS (Annual)$0.20
ROI (Annual)22.71%
Gross Margin (Annual)64.28%
Net Profit Margin (5Y Avg)-9.42%
Cash / Share (Quarterly)$0.81
P/E Basic Excl Extra (TTM)21.79x
Revenue Growth QoQ (YoY)16.19%
P/E Normalized (Annual)21.79x
ROA (Last FY)16.34%
Revenue Growth TTM (YoY)29.95%
EBITD / Share (TTM)$0.20
ROE (5Y Avg)-23.86%
Operating Margin (TTM)12.58%
Cash Flow / Share (Annual)$0.17
P/B Ratio4.95x
P/B Ratio (Quarterly)6.63x
Net Income / Employee (Annual)$0
EV / Revenue (TTM)2.43x
Net Interest Coverage (TTM)-451.17x
ROA (TTM)18.42%
EPS Growth QoQ (YoY)-44.57%
EV / EBITDA (TTM)18.84x
EPS Incl Extra (Annual)$0.20
Current Ratio (Annual)4.86x
Quick Ratio (Quarterly)3.77x
3-Month Avg Trading Volume1.06M
52-Week Price Return-22.80%
EV / Free Cash Flow (Annual)23.78x
P/E Incl Extra (TTM)21.79x
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$0.89
P/S Ratio (Annual)2.93x
Asset Turnover (Annual)1.22x
52-Week High$14.69
Operating Margin (5Y Avg)-10.47%
EPS Excl Extra (Annual)$0.20
CapEx CAGR (5Y)15.84%
26-Week Price Return-36.20%
Quick Ratio (Annual)3.77x
13-Week Price Return-25.82%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)4.86x
Enterprise Value$314.145
Revenue / Share Growth (5Y)9.32%
Asset Turnover (TTM)1.37x
Revenue / Employee (Annual)$1
Inventory Turnover (Annual)3.12x
Pretax Margin (Annual)14.06%
Cash / Share (Annual)$0.81
3-Month Return Std Dev42.95%
Gross Margin (5Y Avg)61.56%
Net Income / Employee (TTM)$0
ROE (Last FY)22.71%
Net Interest Coverage (Annual)-510.50x
EPS Basic Excl Extra (Annual)$0.20
P/FCF (TTM)28.67x
Receivables Turnover (TTM)14.78x
EV / Free Cash Flow (TTM)23.78x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$0.20
Receivables Turnover (Annual)14.78x
ROI (TTM)26.06%
P/S Ratio (TTM)2.93x
Pretax Margin (5Y Avg)-9.23%
Revenue / Share (Annual)$1.51
Tangible BV / Share (Annual)$0.89
Forward P/E17.78x
Price vs S&P 500 (52W)-52.63%
P/E Ratio (TTM)21.79x
EPS Growth TTM (YoY)94.47%
Year-to-Date Return-25.47%
5-Day Price Return5.80%
EPS Normalized (Annual)$0.20
ROA (5Y Avg)-11.53%
Net Profit Margin (Annual)13.43%
Month-to-Date Return7.48%
EBITD / Share (Annual)$0.20
Operating Margin (Annual)12.58%
LT Debt / Equity (Annual)0.00x
P/CF (TTM)28.05x
ROI (5Y Avg)-23.83%
P/E Excl Extra (TTM)21.79x
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$0.20
P/TBV (Quarterly)7.16x
P/B Ratio (Annual)6.63x
Inventory Turnover (TTM)3.12x
Pretax Margin (TTM)14.06%
Book Value / Share (Annual)$0.96
Price vs S&P 500 (13W)-26.51%
Beta2.25x
P/FCF (Annual)28.67x
Revenue / Share (TTM)$1.52
ROE (TTM)26.06%
52-Week Low$4.16
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.27
4.27
4.27
4.27
Industry Peers — Pharmaceutical Preparations(15)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
NAGENiagen Bioscience, Inc. Common Stock | 2.93x | 29.95% | 64.28% | — | $4.73 |
CRONCronos Group Inc. Common Share | 7.06x | 24.63% | 42.81% | -49.98% | $2.68 |
TLRYTilray Brands, Inc. Common Stock | 0.92x | 3.82% | 27.68% | — | $6.79 |
CGCCanopy Growth Corporation Common Shares | 2.42x | 0.59% | 26.56% | — | $1.15 |
USNAUSANA Health Sciences Inc | 0.38x | 5.88% | 78.29% | -37.04% | $19.06 |
SNDLSundial Growers Inc. Common Shares | 0.58x | 2.82% | 27.33% | — | $1.51 |
MDWDMediWound Ltd. | 13.10x | -16.14% | 19.19% | — | $17.10 |
ACBAurora Cannabis Inc. Common Shares | 0.78x | 16.54% | 1.35% | — | $3.61 |
FTLFFitLife Brands, Inc. Common Stock | 1.34x | 1.34% | 37.58% | -20.04% | $9.25 |
BTMDBiote Corp. Class A Common Stock | 0.41x | -2.52% | 71.46% | -26.84% | $2.10 |
NAIINatural Alternatives International Inc. | 0.12x | 10.92% | 9.06% | — | $2.69 |
About
Niagen Bioscience Inc develops NAD+-boosting therapeutics focused on extending healthspan and addressing age-related decline. The company's clinically proven flagship ingredient effectively raises NAD+ levels and serves as the foundation for its product portfolio. Leveraging precision science approaches, Niagen targets the growing healthy-aging market with evidence-based solutions.